OncoMatch/Clinical Trials/NCT05323201
Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
Is NCT05323201 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including fhB7H3.CAR-Ts and Fludarabine for hepatocellular carcinoma.
Treatment: fhB7H3.CAR-Ts · Fludarabine · Cyclophosphamide — This is single center, open-label phase I/II, non-randomized study which will enroll patients with recurrent advanced hepatocellular carcinoma to evaluate the safety, feasibility, and efficacy of fully human B7H3 CAR-T in treating hepatocellular carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Biomarker criteria
Required: CD276 positive expression (positive)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
has received chemotherapy/radiotherapy within the past 4 weeks
Cannot have received: radiation therapy
has received chemotherapy/radiotherapy within the past 4 weeks
Cannot have received: cellular immunotherapy
history of cellular immunotherapy
Cannot have received: antibody therapy
history of ... antibody therapy
Cannot have received: systemic hormone therapy
receiving systemic hormone therapy
Lab requirements
Blood counts
white blood cell count≥ 2.5 × 10^9 / L; hemoglobin≥ 9 g/dL; platelet count≥ 50 × 10^9 / L; lymphocyte proportion≥ 15 %
Kidney function
Serum creatinine< 220μmol/L
Liver function
Child-Pugh A, B grade; ALT and AST≤ 5 × ULN; ALB≥ 30 g/L; Total bilirubin≤ 2.5 × ULN
Cardiac function
Left ventricular ejection fraction≥ 40%; Indoor oxygen saturation ≥ 95 %
Child-Pugh A, B grade. ALT and AST≤ 5 × ULN; ALB≥ 30 g/L； Total bilirubin≤ 2.5 × ULN； Serum creatinine< 220μmol/L; Indoor oxygen saturation ≥ 95 %; Left ventricular ejection fraction≥ 40%; white blood cell count≥ 2.5 × 10^9 / L; hemoglobin≥ 9 g/dL; platelet count≥ 50 × 10^9 / L; lymphocyte proportion≥ 15 %
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify